valproic acid has been researched along with Hypotension in 13 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label, randomized controlled study was conducted at a tertiary care teaching hospital to compare efficacy and safety of intravenous sodium valproate versus diazepam infusion for control of refractory status epilepticus." | 9.12 | Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. ( Mehta, V; Singhi, P; Singhi, S, 2007) |
| " Methylene blue may have utility in the treatment of distributive shock resulting from poisoning refractory to standard vasopressor therapy." | 7.80 | Methylene blue used in the treatment of refractory shock resulting from drug poisoning. ( Braitberg, G; Fisher, J; Graudins, A; Taori, G, 2014) |
| "No patient in the VPA group developed respiratory depression, hypotension, or hepatic dysfunction, whereas in the DZP group, 5." | 6.76 | Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. ( Chen, WB; Fan, CQ; Gao, R; Ren, Y; Su, YY; Wang, L; Zhang, YZ; Zhao, JW, 2011) |
| "In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines." | 5.30 | Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. ( Barsan, W; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, N; Kapur, J; Lowenstein, D; Meinzer, C; Shinnar, S; Silbergleit, R, 2019) |
| "An open-label, randomized controlled study was conducted at a tertiary care teaching hospital to compare efficacy and safety of intravenous sodium valproate versus diazepam infusion for control of refractory status epilepticus." | 5.12 | Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. ( Mehta, V; Singhi, P; Singhi, S, 2007) |
| "Twenty patients with acute repetitive seizures received 20 mg/kg loading doses of valproic acid." | 5.09 | The safety of rapid valproic acid infusion. ( Faught, E; Limdi, NA, 2000) |
| " Methylene blue may have utility in the treatment of distributive shock resulting from poisoning refractory to standard vasopressor therapy." | 3.80 | Methylene blue used in the treatment of refractory shock resulting from drug poisoning. ( Braitberg, G; Fisher, J; Graudins, A; Taori, G, 2014) |
| "A 31-y-old epileptic man developed coma and shock after suicidally ingesting large amounts of valproic acid and gabapentin." | 3.69 | Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning. ( Brady, LA; Do, SM; Fernandez, MC; Kloster, JC; Prosnitz, EH; Ruffenach, SJ; Salmon, JV; Villarin, A; Walter, FG, 1996) |
| "No patient in the VPA group developed respiratory depression, hypotension, or hepatic dysfunction, whereas in the DZP group, 5." | 2.76 | Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. ( Chen, WB; Fan, CQ; Gao, R; Ren, Y; Su, YY; Wang, L; Zhang, YZ; Zhao, JW, 2011) |
| "The hypotension was treated initially with intravenous fluid hydration with normal saline, but the blood pressure correction was transient using this approach." | 1.36 | Probable valproate sodium-associated hypotension. ( Ota, KS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Comstock, G | 1 |
| Kilgallon, K | 1 |
| Wang, GS | 1 |
| Bourne, D | 1 |
| Blanchette, E | 1 |
| Stenson, E | 1 |
| Kapur, J | 1 |
| Elm, J | 1 |
| Chamberlain, JM | 1 |
| Barsan, W | 1 |
| Cloyd, J | 1 |
| Lowenstein, D | 1 |
| Shinnar, S | 1 |
| Conwit, R | 1 |
| Meinzer, C | 1 |
| Cock, H | 1 |
| Fountain, N | 1 |
| Connor, JT | 1 |
| Silbergleit, R | 1 |
| Ge, Y | 1 |
| Xu, B | 1 |
| Zhu, S | 1 |
| Li, C | 1 |
| He, Q | 1 |
| Zhu, T | 1 |
| Fan, R | 1 |
| Gong, D | 1 |
| Fisher, J | 1 |
| Taori, G | 1 |
| Braitberg, G | 1 |
| Graudins, A | 1 |
| Ota, KS | 1 |
| Chen, WB | 1 |
| Gao, R | 1 |
| Su, YY | 1 |
| Zhao, JW | 1 |
| Zhang, YZ | 1 |
| Wang, L | 1 |
| Ren, Y | 1 |
| Fan, CQ | 1 |
| Mehta, V | 1 |
| Singhi, P | 1 |
| Singhi, S | 1 |
| Fernandez, MC | 2 |
| Walter, FG | 1 |
| Kloster, JC | 1 |
| Do, SM | 1 |
| Brady, LA | 1 |
| Villarin, A | 1 |
| Ruffenach, SJ | 1 |
| Prosnitz, EH | 1 |
| Salmon, JV | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Johnson, LZ | 1 |
| Martinez, I | 1 |
| Davis, CP | 1 |
| Kasinath, BS | 1 |
| White, JR | 1 |
| Santos, CS | 1 |
| Sinha, S | 1 |
| Naritoku, DK | 1 |
| Limdi, NA | 1 |
| Faught, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
4 trials available for valproic acid and Hypotension
| Article | Year |
|---|---|
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Double-Blind Method; D | 2019 |
Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Cerebrovascular Disorders; Diazepam; Drug Resistance; Electroencephalo | 2011 |
Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Female; Humans; Hypotension; Infant; Infusions, | 2007 |
The safety of rapid valproic acid infusion.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Blood Pressure; Female; Heart Rate; Humans; Hypotension; I | 2000 |
9 other studies available for valproic acid and Hypotension
| Article | Year |
|---|---|
Management and Associated Toxicokinetics of Massive Valproic Acid Ingestion with High Flow Continuous Venovenous Hemodiafiltration.
Topics: Adolescent; Child; Continuous Renal Replacement Therapy; Drug Overdose; Eating; Female; Hemodiafiltr | 2022 |
Severe Acute Valproic Acid Intoxication Successfully Treated with Liver Support Therapy.
Topics: Adult; Anticonvulsants; Coma; Drug Overdose; Female; Hemofiltration; Humans; Hypotension; Severity o | 2017 |
Methylene blue used in the treatment of refractory shock resulting from drug poisoning.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antidotes; Antipsychotic Agents; B | 2014 |
Probable valproate sodium-associated hypotension.
Topics: Aged; Anticonvulsants; Fluid Therapy; Humans; Hypotension; Infusions, Intravenous; Male; Status Epil | 2010 |
Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning.
Topics: Acetates; Adult; Amines; Anticonvulsants; Biomarkers; Blood Chemical Analysis; Chromatography, Thin | 1996 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Successful treatment of valproic acid overdose with hemodialysis.
Topics: Adult; Drug Overdose; Female; Humans; Hypotension; Poisoning; Renal Dialysis; Valproic Acid | 1999 |
Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.
Topics: Anticonvulsants; Child; Female; Fluid Therapy; Humans; Hypotension; Infusions, Intravenous; Status E | 1999 |
Intravenous valproate is well tolerated in unstable patients with status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Heart Rate; Humans; Hypotension; Infusions, Intraven | 2000 |